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Differential accumulation of tau 
pathology between reciprocal F1 
hybrids of rTg4510 mice
Daijiro Yanagisawa1*, Hamizah Shahirah Hamezah1,2, Aslina Pahrudin Arrozi1 & 
Ikuo Tooyama1*
Tau, a family of microtubule-associated proteins, forms abnormal intracellular inclusions, so-called tau 
pathology, in a range of neurodegenerative diseases collectively known as tauopathies. The rTg4510 
mouse model is a well-characterized bitransgenic F1 hybrid mouse model of tauopathy, which was 
obtained by crossing a Camk2α-tTA mouse line (on a C57BL/6 J background) with a tetO-MAPT*P301L 
mouse line (on a FVB/NJ background). The aim of this study was to investigate the effects of the 
genetic background and sex on the accumulation of tau pathology in reciprocal F1 hybrids of rTg4510 
mice, i.e., rTg4510 on the (C57BL/6 J × FVB/NJ)F1 background (rTg4510_CxF) and on the (FVB/
NJ × C57BL/6 J)F1 background (rTg4510_FxC). As compared with rTg4510_CxF mice, the rTg4510_FxC 
mice showed marked levels of tau pathology in the forebrain. Biochemical analyses indicated that 
the accumulation of abnormal tau species was accelerated in rTg4510_FxC mice. There were strong 
effects of the genetic background on the differential accumulation of tau pathology in rTg4510 mice, 
while sex had no apparent effect. Interestingly, midline-1 (Mid1) was identified as a candidate gene 
associated with this difference and exhibited significant up/downregulation according to the genetic 
background. Mid1 silencing with siRNA induced pathological phosphorylation of tau in HEK293T cells 
that stably expressed human tau with the P301L mutation, suggesting the role of Mid1 in pathological 
alterations of tau. Elucidation of the underlying mechanisms will provide novel insights into the 
accumulation of tau pathology and is expected to be especially informative to researchers for the 
continued development of therapeutic interventions for tauopathies.
Tau belongs to a family of microtubule-associated proteins and was originally identified as a heat-stable protein 
essential for microtubule  assembly1. Human tau is encoded by the MAPT gene on chromosome  17q212 and 
consists of six isoforms, 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R, which are generated by alternative splic-
ing of exon 2 (E2), E3, and  E103–5.
Tau forms abnormal intracellular inclusions, so-called tau pathology, in neurons and glial cells in a range of 
neurodegenerative diseases collectively known as tauopathies, which include Alzheimer’s disease, progressive 
supranuclear palsy, corticobasal degeneration, and Pick’s disease. Tau pathology is characterized by abnormally 
hyperphosphorylated tau molecules that form bundles of paired helical filaments and straight  filaments6,7. In 
1998, missense mutations of tau were identified in patients with frontotemporal dementia associated with par-
kinsonism linked to chromosome  178–10. This discovery demonstrated that the pathological abnormalities of tau 
can be a primary or even the sole cause of  tauopathy7.
rTg4510 is a well-characterized bitransgenic F1 hybrid mouse model of tauopathy. rTg4510 mice were 
originally produced by crossing a responder transgenic mouse (tetO-MAPT*P301L mouse line on a FVB/
NJ background) with an activator transgenic mouse (Camk2α-tTA mouse line on a 129S6 background). The 
responder carries a tetracycline response element placed upstream in a complementary DNA (cDNA) encoding 
human 0N4R tau with a P301L mutation that is linked to hereditary tauopathy, while the activator expresses 
a tetracycline-controlled transactivator (tTA) under the control of the  Ca2+-calmodulin kinase II α (Camk2α) 
 promoter11,12. Consequently, the hybrid F1 mice express human P301L mutant tau in the forebrain at a level 
approximately 13-fold higher than that of endogenous mouse tau and display progressive age-dependent accu-
mulation of tau pathology, which can include abnormal tau phosphorylation and argyrophilic inclusions in the 
forebrain region, decreased dendritic spine density, neurodegeneration, and a variety of cognitive  deficits11–17.
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In a recent study, the original 129S6 background of the Camk2α-tTA mouse line was replaced with the 
C57BL/6 background, one of the most commonly used mouse strains, and reported that the introduction of 
the C57BL/6 background into the rTg4510 mouse background altered the presentation of tau pathology only 
minimally from the original phenotype and with no loss of  fidelity18. In contrast, we previously reported a 
significant difference in the accumulation of tau pathology in male reciprocal F1 hybrids of rTg4510  mice19. In 
addition, Yue et al. reported a sex difference in tau pathology and memory decline in the original rTg4510  mice20. 
The importance of the genetic background and sex in the phenotype of transgenic mouse model is well known. 
Therefore, in the present study, the mechanisms underlying differential tau accumulation in rTg4510 mice were 
investigated, while focusing on the effects of the genetic background and sex. A deeper understanding of tau 
pathology will be useful for the development of therapeutic regimens for tauopathies.
Results
Differential accumulation of tau pathology between reciprocal F1 hybrids. Reciprocal F1 
hybrids of rTg4510 mice consisting of two genetic backgrounds (Table 1) were used in this study: rTg4510 mice 
on a (C57BL/6 J × FVB/NJ)F1 (maternal strain × paternal strain) background (rTg4510_CxF) and rTg4510 mice 
on a (FVB/NJ × C57BL/6 J)F1 background (rTg4510_FxC). To investigate the accumulation of tau pathology, 
histological analysis was performed of coronal brain sections from male and female rTg4510_CxF and rTg4510_
FxC mice at 6 months of age. Immunohistochemical analysis of human tau (HT7) revealed a high level of immu-
noreactivity in the cerebral cortex and hippocampus in all groups although there were no significant differences 
(Fig. 1A). Immunohistochemical analysis of phosphorylated tau (AT8) and Gallyas silver staining unveiled a 
large number of positively stained structures in the cerebral cortex and hippocampus of rTg4510 mice (Fig. 1A). 
Quantitative analysis was performed of the AT8-immunoreactive areas and Gallyas-positive stained areas of the 
cerebral cortex of rTg4510 mice. Two-way ANOVA with the genetic background and sex as factors revealed that 
the genetic background had the most profound effect [F (1, 20) = 31.18, p < 0.0001], while sex had no effect [F 
(1, 20) = 3.37, p = 0.0813] in the AT8-immunoreactive areas of the cerebral cortex (Fig. 1B). Subsequent analysis 
with the Mann–Whitney U test indicated significantly greater AT8-immunoreactivity in rTg4510_FxC mice 
than rTg4510_CxF mice (p < 0.0001; Fig. 1C). Furthermore, two-way ANOVA with the genetic background and 
sex as factors revealed that the genetic background had the most profound effect [F (1, 20) = 45.74, p < 0.0001], 
while sex had no effect [F (1, 20) = 3.726, p = 0.0679] in the Gallyas-positive stained areas of the cerebral cortex 
(Fig. 1D). Gallyas-positive staining of rTg4510_FxC mice was significantly greater than that of rTg4510_CxF 
mice (p < 0.0001; Fig. 1E). Quantitative analysis also revealed that the genetic background, but not sex, had a 
significant main effect in the AT8-immunoreactive areas and Gallyas-positive stained areas of the hippocampus, 
and significantly higher levels of these areas in rTg4510_FxC mice, as compared with rTg4510_CxF mice (Sup-
plementary Fig. S1, Table S1). These results suggest more severe accumulation of tau pathology in rTg4510_FxC 
mice than rTg4510_CxF mice. In addition, there was no significant sex difference in the accumulation of tau 
pathology detected in rTg4510 mice.
Soluble and insoluble tau accumulation differs according to the genetic background. Western 
blot analysis of the TBS-soluble and sarkosyl-insoluble fractions extracted from the cerebral cortex of rTg4510 
mice was performed to investigate the accumulation of soluble and insoluble tau in the brain. With the use of 
polyclonal (Tau) and monoclonal (HT7) antibodies, Tau was detected at 55 kDa as a major band and at around 
64 kDa as a minor band in the TBS-soluble fraction (Fig. 2A); however, sarkosyl-insoluble tau was only detected 
at around 64 kDa (Fig. 2B). Two-way ANOVA (genetic background × sex) of the densitometric analysis results 
revealed no effect of the genetic background [F (1, 20) = 0.495, p = 0.4898 for Tau, F (1, 20) = 0.5535, p = 0.4656 
for HT7] or sex [F (1, 20) = 0.2426, p = 0.6277 for Tau, F (1, 20) = 0.3885, p = 0.5401 for HT7] on 55-kDa tau levels 
in the TBS-soluble fraction (Fig. 2C,G). In contrast, two-way ANOVA (genetic background × sex) revealed a 
significant main effect of the genetic background [F (1, 20) = 17.12, p = 0.0005 for Tau, F (1, 20) = 23.49, p < 0.0001 
for HT7], but not sex [F (1, 20) = 1.118, p = 0.3030 for Tau, F (1, 20) = 3.783, p = 0.0660 for HT7], on 64-kDa tau 
levels in the TBS-soluble fraction (Fig. 2D,H). The level of 64-kDa tau in the TBS-soluble fraction was signifi-
cantly higher in rTg4510_FxC mice than rTg4510_CxF mice (p = 0.0005 for Tau, p = 0.0003 for HT7; Fig. 2E,I). 
In the sarkosyl-insoluble fraction, the genetic background and sex had no effect on 64-kDa tau levels probed 
with the polyclonal antibody (Tau), as determined by two-way ANOVA (Fig. 2F). In contrast, two-way ANOVA 
(genetic background × sex) revealed that the genetic background had a significant main effect [F (1, 20) = 5.937, 
p = 0.0243], but not sex [F (1, 20) = 0.7476, p = 0.3975], on sarkosyl-insoluble tau levels probed with the HT7 
antibody (Fig. 2J). The level of sarkosyl-insoluble tau probed with HT7 was significantly higher in rTg4510_FxC 
mice than rTg4510_CxF mice (p = 0.0197; Fig. 2K). These results suggest greater accumulation of abnormal tau 
species detected at around 64 kDa in rTg4510_FxC mice, as compared with rTg4510_CxF mice, although there 
Table 1.  The genetic backgrounds of the two mouse strains obtained by reciprocal crosses.
Offspring
Genetic background (maternal 
strain × paternal strain)F1
Parents
Maternal strain Paternal strain
CxF (C57BL/6 J × FVB/NJ)F1 C57BL/6 J (Hemizygous Camk2α-tTA) FVB/NJ (Hemizygous tetO-MAPT*P301L)
FxC (FVB/NJ × C57BL/6 J)F1 FVB/NJ (Hemizygous tetO-MAPT*P301L) C57BL/6 J (Hemizygous Camk2α-tTA)
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was no significant difference between groups in normal tau protein levels, which are generally measured in 
soluble protein extracts at 55 kDa.
Effect of genetic background on the abnormal phosphorylation of tau. Subsequently, western 
blot analysis of abnormally phosphorylated tau in the TBS-soluble and sarkosyl-insoluble fractions was per-
formed. Phosphorylated tau probed with AT8 (pSer202 and pThr205), AT180 (pThr231), and AT270 (pThr181) 
in the TBS-soluble fraction was revealed as a major band at 64-kDa and a minor band at 55-kDa, while AT100 
(pThr212 and pSer214) showed only a 64-kDa band (Fig. 3A). In the sarkosyl-insoluble fraction, phosphoryl-
ated tau probed with AT8, AT100, AT180, and AT270 was only detected at around 64 kDa (Fig. 3B). Following 
densitometric analysis of the TBS-soluble fraction, two-way ANOVA (genetic background × sex) revealed no 
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Figure 1.  Abnormally phosphorylated tau and Gallyas-positive structures in the brains of rTg4510 mice at 
6 months of age. (A) Representative photographs of the immunohistochemical results for human tau (clone 
HT7), phosphorylated tau (clone AT8), and Gallyas silver staining. Scale bar: 1 mm. (B–E) Quantitative 
analysis of the AT8-immunoreactive area and Gallyas-positive stained area. Two-way ANOVA (genetic 
background × sex) revealed a main effect of the genetic background, but no effect of sex, in the AT8-
immunoreactive area (B) and Gallyas-positive stained area (D) of the cerebral cortex (Supplementary Table S1). 
The Mann–Whitney U test revealed significantly higher levels of AT8-immunoreactivity (C) and Gallyas-
positive staining (E) in samples obtained from the rTg4510_FxC mice, as compared with the rTg4510_CxF 
mice. The rTg4510_CxF and rTg4510_FxC groups contained six males and six females each (n = 12/group). 
Data are presented as the mean ± SEM. ***p < 0.001 (Mann–Whitney U test).
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(1, 20) = 0.2224, p = 0.6424 for AT270] or sex [F (1, 20) = 0.01865, p = 0.8927 for AT8, F (1, 20) = 0.3825, p = 0.5432 
for AT180, F (1, 20) = 0.197, p = 0.6619 for AT270] on levels of 55-kDa phosphorylated tau (Fig. 3C,K,P). In 
contrast, two-way ANOVA (genetic background × sex) revealed a significant main effect of the genetic back-
ground [F (1, 20) = 7.854, p = 0.0110 for AT8, F (1, 20) = 10.81, p = 0.0037 for AT100, F (1, 20) = 12.75, p = 0.0019 
for AT180, F (1, 20) = 19.72, p = 0.0003 for AT270], but not sex [F (1, 20) = 0.8822, p = 0.3588 for AT8, F (1, 
20) = 1.425, p = 0.2466 for AT100, F (1, 20) = 2.527, p = 0.1276 for AT180, F (1, 20) = 3.219, p = 0.0879 for AT270], 
on levels of 64-kDa phosphorylated tau in the TBS-soluble fraction (Fig. 3D,G,L,Q). The levels of 64-kDa phos-
phorylated tau in the TBS-soluble fraction were significantly higher in rTg4510_FxC mice than rTg4510_CxF 
mice (p = 0.0121 for AT8, p = 0.0029 for AT100, p = 0.0045 for AT180, p = 0.0004 for AT270; Fig.  3E,H,M,R). 
Probing of phosphorylated tau in the sarkosyl-insoluble fraction with AT100 and AT180 revealed a signifi-
cant main effect of the genetic background [F (1, 20) = 4.72, p = 0.0420 for AT100, F (1, 20) = 4.868, p = 0.0392 











































































































































































































































































































A. TBS-soluble fraction B. Sarkosyl-insoluble fraction
C D E F
G H I J K
TBS-soluble fraction Sarkosyl-insoluble fraction
Figure 2.  Accumulation of soluble and insoluble tau in rTg4510 mice at 6 months of age. (A,B) Representative 
images of western blots for Tau and HT7 in the TBS-soluble fraction (A) and sarkosyl-insoluble fraction (B) 
of the cerebral cortex. β-actin was used as a loading control. The band images in each row were obtained from 
the same gel with separation of the CxF and FxC samples. Full-length blots are presented in Supplementary 
Figure S11. (C–K) Densitometric analysis of tau accumulation. Two-way ANOVA (genetic background × sex) 
revealed a main effect of the genetic background, but no effect of sex, on levels of Tau (D) and HT7 (H) at 
64 kDa in the TBS-soluble fraction and HT7 (J) in the sarkosyl-insoluble fraction (Supplementary Table S1). 
The Mann–Whitney U test revealed significantly higher levels of Tau (E) and HT7 (I) at 64 kDa in the TBS-
soluble fraction and HT7 (K) in the sarkosyl-insoluble fraction from rTg4510_FxC mice, as compared with 
rTg4510_CxF mice. The rTg4510_CxF and rTg4510_FxC groups contained six males and six females each 
(n = 12/group). Data are presented as the mean ± SEM. ***p < 0.001, *p < 0.05 (Mann–Whitney U test).
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A. TBS-soluble fraction B. Sarkosyl-insoluble fraction
C D E F
G H I J
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TBS-soluble fraction Sarkosyl-insoluble fraction
Figure 3.  Accumulation of abnormally phosphorylated tau in rTg4510 mice at 6 months of age. (A,B) Representative images 
of western blots of phosphorylated tau (AT8, AT100, AT180, and AT270) in the TBS-soluble fraction (A) and sarkosyl-
insoluble fraction (B) from the cerebral cortex. The band images of each row were obtained from same gel with separation 
of the CxF and FxC samples. Full-length blots are presented in Supplementary Figure S12. (C–S) Densitometric analysis 
of phosphorylated tau. Two-way ANOVA (genetic background × sex) revealed a main effect of the genetic background, but 
no effect of sex, on the levels of AT8 (D), AT100 (G), AT180 (L), and AT270 (Q) at 64 kDa in the TBS-soluble fraction, and 
AT100 (I) and AT180 (N) in the sarkosyl-insoluble fraction (Supplementary Table S1). The Mann–Whitney U test revealed 
significantly higher levels of AT8 (E), AT100 (H), AT180 (M), and AT270 (R) at 64 kDa in the TBS-soluble fraction and 
AT100 (J) and AT180 (O) in the sarkosyl-insoluble fraction of the rTg4510_FxC mice, as compared with the rTg4510_FxC 
mice. The rTg4510_CxF and rTg4510_FxC groups contained six males and six females each (n = 12/group). Data are presented 
as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05 (Mann–Whitney U test).
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determined by two-way analysis of variance (ANOVA) (Fig. 3I,N), while the genetic background and sex had 
no effect on phosphorylated tau in the sarkosyl-insoluble fraction with the use of the AT8 and AT270 probes 
(Fig. 3F,S). Probing of the sarkosyl-insoluble fraction with AT100 and AT180 revealed significantly higher levels 
of phosphorylated in rTg4510_FxC mice than rTg4510_CxF mice (p = 0.0377 for AT100, p = 0.0284 for AT180; 
Fig.  3J,O). We further analyzed the ratios of phosphorylated tau to total tau which were detected at 55 and 
64 kDa in the TBS-soluble fraction and at 64 kDa in the sarkosyl-insoluble fraction (Supplementary Fig. S2). 
There were no significant changes in the ratio of phosphorylated tau to total tau, which was detected at 55 kDa 
in the TBS-soluble fraction (Supplementary Fig. S2). A two-way ANOVA (genetic background × sex) revealed 
an effect of genetic background, but no effect of sex on the ratios of AT8 [F (1, 20) = 6.813, p = 0.0168 for genetic 
background, F (1, 20) = 2.257, p = 0.1486 for sex], AT100 [F (1, 20) = 8.999, p = 0.0071 for genetic background, 
F (1, 20) = 0.7756, p = 0.3889 for sex], and AT180 [F (1, 20) = 6.853, p = 0.0184 for genetic background, F (1, 
20) = 2.11, p = 0.1619 for sex], but not AT270 [F (1, 20) = 1.06, p = 0.3155 for genetic background, F (1, 20) = 1.506, 
p = 0.2340 for sex], to total tau, which was detected at 64 kDa in the TBS-soluble fraction. The Mann–Whitney 
U test revealed significantly higher ratios of AT8, AT100, and AT180 to total tau in rTg4510_FxC mice com-
pared with rTg4510_FxC mice (p = 0.0100 for AT8, p = 0.0055 for AT100, p = 0.0242 for AT180; Supplementary 
Fig. S2). A two-way ANOVA of the ratios of AT100 and AT180 to total tau in the sarkosyl-insoluble fraction pri-
marily revealed effects of genetic background [F (1, 20) = 5.425, p = 0.0304 for AT100, F (1, 20) = 10.6, p = 0.0040 
for AT180], but no effect of sex [F (1, 20) = 0.02554, p = 0.8746 for AT100, F (1, 20) = 0.4481, p = 0.5109 for 
AT180] in rTg4510 mice. The Mann–Whitney U test revealed significantly higher ratios of AT100 and AT180 
to total tau in rTg4510_FxC mice compared with rTg4510_FxC mice (p = 0.0464 for AT8, p = 0.0038 for AT100; 
Supplementary Fig. S2). Taken together, these results suggest that the genetic background of rTg4510 mice may 
affect not only the increase in the levels of abnormal tau, but also the increase in the ratio of tau phosphorylation, 
in particular at the AT100 and AT180 sites, and in part at the AT8 site.
No difference in tau mRNA levels between reciprocal F1 hybrids. Next, the effects of the genetic 
background on tau mRNA levels were investigated. The mRNA levels of transgenic human P301L tau, which 
were undetectable in wild-type (WT) mice on a (C57BL/6  J × FVB/NJ)F1 background (WT_CxF) and on a 
(FVB/NJ × C57BL/6 J)F1 background (WT_FxC), had no effect on the genetic background or sex of rTg4510 
mice [two-way ANOVA (genetic background × sex); F (1, 20) = 1.086 p = 0.3099 for genetic background, F 
(1, 20) = 1.916, p = 0.1816 for sex; Fig. 4A]. The mRNA levels of mouse tau were similar in rTg4510 and WT 
mice. Two-way ANOVA (genetic background × sex) revealed that the genetic background and sex had no 
effect on mouse tau mRNA levels in the WT mice [F (1, 16) = 0.07445, p = 0.7885 for genetic background, F (1, 
16) = 0.09461, p = 0.7624 for sex] or rTg4510 mice [F (1, 20) = 1.765, p = 0.1990 for genetic background, F (1, 
20) = 2.929e-005, p = 0.9957 for sex; Fig. 4B]. These results suggest that the mouse tau mRNA levels were not 
affected by the genetic background.
Identification of a gene related to the differential accumulation of tau in rTg4510 mice. We 
attempted to identify genes related to the difference in tau accumulation between rTg4510_CxF and rTg4510_
FxC mice. Transgene insertion has been reported to cause a 244-kb deletion on chromosome 14 of tetO-
MAPT*P301L mice, which affects Fgf14 and a 508-kbp deletion on chromosome 12 of Camk2α-tTA mice, which 




































































Figure 4.  The mRNA levels of human P301L tau and mouse tau in rTg4510 mice at 6 months of age. qPCR 
analyses of transgenic human P301L tau (A) and endogenous mouse tau (B) in WT and rTg4510 mice were 
conducted. Two-way ANOVA (genetic background × sex) revealed no effects of the genetic background or sex 
on the mRNA levels of transgenic human P301L tau and endogenous mouse tau (Supplementary Table S2). The 
WT_CxF and WT_FxC groups contained four males and four females each (n = 8/group). The rTg4510_CxF 
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background had any effect of the mRNA levels of particular genes in WT and rTg4510 mice. However, the 
results revealed no significant effects of the genetic background on the mRNA levels of the tested genes between 
reciprocal F1 hybrids (Supplementary Fig. S3, Table S2, S3). Subsequently, we investigated whether there were 
differences in the mRNA levels of disease-associated tau kinases and select phosphatases, namely cyclin-depend-
ent-like kinase 5, dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1, glycogen synthase 
kinase-3 β, casein kinase 1 alpha 1, microtubule affinity-regulating kinase 1 (Mark1), Mark2, Mark3, Mark4, 
protein kinase cAMP-activated catalytic subunit alpha, and protein phosphatase 2 catalytic subunit alpha. How-
ever, the genetic background and sex had no effect of on the mRNA levels of these genes (Supplementary Fig. S4, 
Table S2, S3).
Next, qPCR analysis of 10 upregulated and downregulated genes was performed (Fig. 4, Supplementary 
Fig. S5, S6, Table S4), based on the RNA-seq analysis results of male WT_CxF (n = 1) and male WT_FxC (n = 1) 
mice. The results revealed a significant difference in the mRNA levels of midline-1 (Mid1) between reciprocal F1 
hybrids. Two-way ANOVA (genetic background × sex) revealed that the genetic background, but not sex, had a 
significant effect on Mid1 levels in WT mice [F (1, 16) = 7.832, p = 0.0129 for genetic background, F (1, 16) = 1.577, 
p = 0.2273 for sex] and rTg4510 mice [F (1, 20) = 32.46, p < 0.0001 for genetic background, F (1, 20) = 0.2321, 
p = 0.6352 for sex; Fig. 5A]. The levels of Mid1 in WT_CxF and rTg4510_CxF mice were significantly higher 
than those in WT_FxC and rTg4510_FxC mice, respectively (p = 0.0122 for WT, p = 0.0007 for rTg4510; Fig. 5B).
Tau accumulation and Mid1 mRNA levels in rTg4510 mice at 3 months of age. Histological 
and western blot analyses of male and female rTg4510_CxF and rTg4510_FxC mice at 3 months of age were 
performed. Histological analysis showed no significant differences in AT8-immunoreactivity and Gallyas-pos-
itive staining between rTg4510_CxF and rTg4510_FxC mice (Supplementary Fig.  S7). Western blot analysis 
of the TBS-soluble fraction showed significant differences in AT8 levels, but not levels of HT7, AT180, and 
AT270 (Supplementary Fig. S8A-K). By two-way ANOVA (genetic background × sex), there was a main effect 
of the genetic background, but not sex, on AT8 levels at 55 kDa [F (1, 12) = 5.919, p = 0.0316 for genetic back-
ground, F (1, 12) = 0.5805, p = 0.4608 for sex] and 64 kDa [F (1, 12) = 12.9, p = 0.0037 for genetic background, F 
(1, 12) = 0.8891, p = 0.3643 for sex; Supplementary Fig. S8D and E], while the Mann–Whitney U test revealed 
significantly high levels of AT8 at 55 kDa (p = 0.0207) and 64 kDa (p = 0.0207) in rTg4510_FxC mice, as com-
pared with rTg4510_CxF mice (Supplementary Fig. S8F and G). In contrast, two-way ANOVA (genetic back-
ground × sex) revealed no effects of the genetic background or sex on the levels of HT7, AT8, AT100, AT180, and 
AT270 in the sarkosyl-insoluble fractions between the rTg4510_CxF and rTg4510_FxC mice (Supplementary 
Fig. S8L-Q).
The genetic background, but not sex, had an effect on Mid1 mRNA levels in rTg4510 mice at 3 months of 
age, as determined by two-way ANOVA (genetic background × sex) [F (1, 12) = 6.733, p = 0.0234 for genetic 
background, F (1, 12) = 0.6322, p = 0.4420 for sex; Supplementary Fig. S9A]. The Mann–Whitney U test revealed 
significantly lower Mid1 mRNA levels in rTg4510_FxC mice, as compared with rTg4510_CxF mice (p = 0.0095; 
Supplementary Fig. S9B).
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Figure 5.  The Mid1 gene may be related to differential accumulation of tau. (A) Two-way ANOVA (genetic 
background × sex) of the qPCR results revealed a main effect of the genetic background, but no effect of sex, on 
the mRNA levels of Mid1 in WT and rTg4510 mice (Supplementary Table S3). (B) The Mann–Whitney U test 
revealed significantly higher Mid1 mRNA levels in WT_CxF than in WT_FxC mice and in rTg4510_CxF as 
compared with rTg4510_FxC mice. The WT_CxF and WT_FxC groups contained five males and five females 
each (n = 10/group). The rTg4510_CxF and rTg4510_FxC groups contained six males and six females each 
(n = 12/group). Data are presented as the mean ± SEM. **p < 0.01, *p < 0.05 (Mann–Whitney U test).
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MID1 silencing induced pathological phosphorylation of tau. To investigate the role of Mid1 in 
tau phosphorylation and accumulation, MID1 silencing was performed with siRNA in HEK293T cells stably 
expressing human tau with the P301L mutation. The qPCR results showed that MID1 mRNA levels were reduced 
by 88% in MID1-knockdown cells, as compared with control cells (Fig. 6A). Western blot analysis of the TBS-
soluble fraction showed no significant differences in the levels of HT7, AT180, and AT270 at 55 kDa between 
cells treated with negative control siRNA and MID1 siRNA (Fig. 6B–E). MID1-knockdown cells showed a sig-
nificant increase in AT180 levels at 64 kDa (p = 0.0206, Student’s t-test) and slight, but not significant, increases 
in the levels of HT7, AT8 and AT270 at 64 kDa (Fig. 6F–I). Western blot analysis of the sarkosyl-insoluble frac-
tions of MID1-knockdown cells was also performed; however, no bands were detectable with the use of the HT7, 
AT8, AT180, and AT270 antibodies (data not shown). We further analyzed the ratios of phosphorylated tau to 
total tau; however, there were no significant differences in these ratios between cells treated with negative control 
siRNA and MID1 siRNA (Supplementary Fig. S10).
No relationship of the number of siblings, body weight, and brain weight with differential tau 
pathology. We finally investigated whether the genetic background resulted in changes to the number of 
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Figure 6.  The level of tau accumulation and phosphorylation in MID1-knockdown cells. HEK293T cells stably 
expressing human tau with the P301L mutation were treated with negative control siRNA (NC) and MID1 
siRNA (KD) for 48 h. (A) MID1 mRNA levels in NC-treated and MID1-knockdown cells. (B) Western blots of 
HT7, AT8, AT180, AT270, and β-actin in the TBS-soluble fractions. Arrows and arrowheads indicate bands at 
55 and 64 kDa, respectively. Full-length blots are presented in Supplementary Figure S13. (C–I) Densitometric 
analysis. Data are presented as the mean ± SEM of three independent experiments. *p < 0.05 (Student’s t-test).
Table 2.  Summary of the number of siblings, body weights, and brain weights.
Mouse Sex No. of siblings Body weight (g) Wet weight of the cerebral cortex (mg)
WT_CxF
Male 7.4 ± 0.8 29.5 ± 0.5 100.1 ± 4.3
Female 7.1 ± 0.8 26.4 ± 0.5 108.0 ± 4.4
WT_FxC
Male 8.9 ± 0.9 35.9 ± 1.5 107.1 ± 3.2
Female 8.3 ± 1.4 31.0 ± 1.8 117.5 ± 4.1
rTg4510_CxF
Male 6.8 ± 0.8 27.0 ± 0.6 79.1 ± 4.8
Female 7.6 ± 0.3 22.9 ± 0.6 79.7 ± 3.2
rTg4510_FxC
Male 7.8 ± 0.9 28.7 ± 0.8 75.7 ± 4.1
Female 8.0 ± 1.1 23.1 ± 1.2 68.4 ± 4.1
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background or sex on the number of siblings in WT mice [F (1, 24) = 1.607, p = 0.2171 for genetic background, 
F (1, 24) = 0.1785, p = 0.6764 for sex] or rTg4510 mice [F (1, 32) = 0.7536, p = 0.3918 for genetic background, F 
(1, 32) = 0.3612, p = 0.5521 for sex]. However, the genetic background and sex had significant effects on the body 
weight of WT mice [F (1, 24) = 20.02, p = 0.0002 for genetic background, F (1, 24) = 10.43, p = 0.0036 for sex], 
while sex, but not the genetic background, had an effect the body weight of rTg4510 mice [F (1, 32) = 1.432, 
p = 0.2402 for genetic background, F (1, 32) = 34.68, p < 0.0001 for sex]. Furthermore, sex, but not the genetic 
background, had an effect on the wet weight of the cerebral cortex in WT mice [F (1, 16) = 4.268, p = 0.0554 for 
genetic background, F (1, 16) = 5.151, p = 0.0374 for sex], but not in rTg4510 mice [F (1, 20) = 3.181, p = 0.0897 
for genetic background, F (1, 20) = 0.678, p = 0.4200 for sex]. Based on these results, the number of siblings, body 
weight, and brain weight appear to have no effect differential tau accumulation in rTg4510 mice.
Discussion
We investigated tau pathology in reciprocal F1 hybrids of rTg4510 mice at 3 and 6 months of age. The results 
showed more severe pathological tau accumulation and phosphorylation in rTg4510_FxC mice than rTg4510_
CxF mice with no obvious sex difference at 6 month of age. In contrast, there were no obvious effects of the 
genetic background or sex on pathological alterations of tau in rTg4510 mice at 3 months of age. There was, 
however, a significant difference in Mid1 mRNA levels between the reciprocal F1 hybrids, and MID1 silencing 
with siRNA induced pathological phosphorylation of tau in HEK293T cells stably expressing human tau with the 
P301L mutation. These findings suggest that downregulation of Mid1 contributes to severe pathological altera-
tions of tau in rTg4510_FxC mice, although the effect might be somewhat weak and will require a considerable 
amount of time to be apparent in the in vivo brain.
The Mid1 gene is located on the X chromosome and encodes a 667-amino acid protein that belongs to the 
tripartite motif family and consists of a RING finger domain, two B-box domains, a coiled-coil region, a fibronec-
tin type III domain, and B30.2 domains. The Mid1 protein has been shown to function as an E3 ubiquitin ligase 
targeting the microtubule-associated catalytic subunit of protein phosphatase 2A (PP2Ac) in ubiquitin-mediated 
 degradation22. The Mid1 protein is, however, involved in signaling of mammalian target of rapamycin complex 1 
through the regulation of PP2A  activity23. PP2A is a phosphatase that targets tau and mTOR signaling is known 
to regulate tau phosphorylation and  degradation24. Considering the previous studies cited above, Mid1 upregu-
lation would be expected to increase tau phosphorylation and accumulation through the inhibition of PP2A 
degradation and the activation of mTOR, which contradicts the results of the present study. Therefore, it is of 
interest to investigate the difference in the level/activity of PP2A between reciprocal F1 hybrids of rTg4510 mice 
in future studies. However, it is difficult to predict the role of Mid1 in the accumulation of tau pathology, since 
it has been reported to serve other functions, such as the regulation of mRNA translation by direct association 
with the  mRNA25. Furthermore, mutations to the Mid1 gene have been identified in patients with X-linked Opitz 
G/BBB syndrome, an inherited multiple-organ disorder primarily affecting midline  structures26,27, although the 
pathological mechanisms remain unknown. Taken together, although the role of Mid1 in pathological alterations 
of tau in the in vivo brain remains to be elucidated, the results of the present study provide novel insight into the 
mechanism underlying the pathological alterations of tau in tauopathy.
Although the mechanisms underlying the difference in Mid1 levels between mice with the (C57BL/6 J × FVB/
NJ)F1 and (FVB/NJ × C57BL/6 J)F1 backgrounds are currently unclear, we expect that epigenetic mechanisms 
are involved, as it has been proposed that maternal care and environmental factors (e.g., diet, stress, etc.) may 
influence epigenetic changes in  offspring28,29. Mice on the (C57BL/6 J × FVB/NJ)F1 background are delivered 
from mothers on a C57BL/6 J background, while mice on the (FVB/NJ × C57BL/6 J)F1 background are delivered 
from mothers on a FVB/NJ background. Therefore, maternal strain-dependent epigenetic changes may occur in 
offspring between the prenatal period and weaning; consequently, expression levels of genes, including Mid1, 
would differ depending on the maternal strain.
Mitochondrial DNA (mtDNA) has also been suspected in the differential accumulation of tau, because of 
its maternal inheritance. A previous study reported variations in mtDNA between strains C57BL/6 J and FVB/
NJ30,31. Specifically, the authors reported a G to T substitution at position 7778, which results in an amino acid 
substitution (aspartic acid to tyrosine) in adenosine triphosphate synthase 8. In addition, a T to C substitution 
at position 9461 resulted in no amino acid change (methionine to methionine) in NADH dehydrogenase 3. 
Furthermore, polymorphic variants contribute to some phenotypic differences in  mice32,33. Mitochondria are 
the powerhouses of the cell, generating cellular energy in the form of ATP through oxidative phosphorylation 
(OXPHOS)34. Mammalian mtDNA encodes 13 polypeptides that are subunits of OXPHOS complexes, 22 transfer 
RNAs, and two ribosomal RNAs that are necessary for the translation of 13 polypeptides. Hence, mtDNA muta-
tions affect energy production via the OXPHOS  system34–36. Since maintaining electrochemical gradients and 
releasing and recycling synaptic vesicles are highly energy-demanding processes, neurons rely almost exclusively 
on the mitochondrial OXPHOS system to fulfill their energy  needs37,38, which suggests that the OXPHOS sys-
tem plays an important role in neural function. A recent study by Kimura et al.39 reported that low-frequency 
stimulation induces the accumulation of sarkosyl-insoluble tau aggregates in the hippocampus of aged WT mice, 
suggesting an important contribution of synaptic impairment to the formation of tau pathology. Taken together, 
mtDNA variants possibly cause disturbances in neural function, such as synaptic impairment, which may result 
in enhanced formation of tau pathology. Furthermore, mitochondrial oxidative stress caused by sod2 knockout 
was reported to induce hyperphosphorylation of tau in a Tg2576 mouse model of Alzheimer’s  disease40. Since 
the mitochondrial OXPHOS system also generates reactive oxygen species, such as superoxide anion radicals, 
mitochondria have antioxidant defense systems to maintain redox homeostasis in the cell. However, according 
to the findings of previous studies, an imbalance in redox homeostasis would contribute to the accumulation of 
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tau pathology. Based on these pieces of evidence, distinct mtDNA variants in rTg4510 mice are considered to 
potentially explain mechanisms underlying phenotypic differences, such as variations in levels of tau pathology.
It is difficult to explain the mechanisms underlying gene expression patterns in rTg4510 mice. Fgf14 levels 
were expected to be reduced in rTg4510 mice due to transgene integrations. However, the results showed that 
Fgf14 levels in rTg4510 mice were much higher than in WT mice, which is in agreement with previous  findings41. 
Dysregulation of Fgf14 mRNA splice variants has been suggested to contribute to the increase in Fgf14  levels41; 
however, the detailed mechanism remains unknown. Considering the findings of Fgf14 expression in rTg4510 
mice, it is probable that unknown mechanisms may induce the expression of other genes, such as Vipr2, Wdr60, 
Esyt2, D430020J02Rik, and Ncapg2, although the expression levels of these genes are expected to be decreased 
due to transgene integrations. In addition, the result showing that Hspa1b expression in rTg4510_FxC mice was 
significantly lower than in rTg4510_CxF mice suggests that the downregulation of Hspa1b may contribute to 
severe pathological accumulation of tau in rTg4510_FxC mice, because Hspa1b (HSP70) has been reported to 
inhibit and degrade tau  aggregation42,43.
The results of the present study raise concerns about the use of rTg4510 mice as models for the evaluation of 
therapeutic interventions of tau pathology. No study, except for our previous  work19, has investigated tau pathol-
ogy levels in reciprocal F1 hybrids of rTg4510 mice. We used Camk2α-tTA mice on a C57BL/6 J background, 
rather than the original 129S6  background11,12. Accordingly, differences in tau pathology levels may only occur in 
Camk2α-tTA mice on a C57BL/6 J background. In contrast, sex had no effect on pathological tau accumulation 
in the present study, while there was a sex difference in pathological tau accumulation in the original rTg4510 
mice, which was more severe in females than  males20. Furthermore, it has been confirmed that there are differ-
ences in the effect of the Y chromosome, mtDNA, maternal care, and environmental factors between reciprocal 
hybrid offspring. Therefore, it is important to take the genetic background into consideration when evaluating 
tau pathology in hybrid rTg4510 mice.
The results of this study revealed a strong effect of the genetic background on the differential accumulation of 
tau pathology between reciprocal F1 hybrids of rTg4510 mice, while there was no evident significant effect of sex. 
Comparisons between the two hybrids indicate that Mid1 may be associated with the differential accumulation 
of tau pathology. Hence, elucidation of the mechanisms underlying differences in tau pathology levels would 
provide novel insights into the accumulation of tau pathology in tauopathy. Furthermore, such findings would 
be beneficial to researchers developing therapeutic interventions for tauopathies.
Methods
Animals. All animal experiments complied with the ARRIVE guidelines, were carried out in accordance 
with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 
8023, revised 1978), and were approved by the Animal Care and Use Committee at the Shiga University of Medi-
cal Science (approval no. 2018–6-5). All efforts were made to minimize animal suffering.
To obtain rTg4510 mice, the hemizygous Camk2α-tTA mouse line (on the C57BL/6 J background; 007,004; 
The Jackson Laboratory, Bar Harbor, ME, USA), carrying a tTA that consisted of the tet-off open reading frame 
placed downstream of Camk2α promoter elements, was crossbred with the hemizygous tetO-MAPT*P301L 
mouse line (on the FVB/NJ background; 015,815; The Jackson Laboratory) carrying human 0N4R tau cDNA 
with the P301L mutation placed downstream of a tetracycline-operon-responsive element. Consequently, mice 
harboring both the activator and responder genes were obtained and used as rTg4510 mice in the present study. 
The Camk2α-tTA mouse line on the C57BL/6 J background, rather than the original 129S6 background, was 
used in this study. Therefore, the mice obtained in this study had either the (C57BL/6 J × FVB/NJ)F1 or (FVB/
NJ × C57BL/6 J)F1 background (Table 1). Littermates expressing neither the activator nor the responder were 
used as WTs. Two to four mice were housed per standard laboratory cage on wood shavings and fed a standard 
chow diet and maintained at 23ºC under a 12-h light/dark cycle (lights on at 08:00–20:00 h) with free access to 
water and food in a specific pathogen-free animal facility.
Preparation of brain extracts. Mice were sacrificed at 3 and 6 months of age with an overdose injection 
of sodium pentobarbital (200 mg/kg, i.p.). Brains were quickly removed and cut into two hemispheres. Cerebral 
cortex tissues were isolated from the right hemisphere, snap frozen in liquid nitrogen, and stored at − 80 °C. 
Sarkosyl-insoluble tau was purified as described  previously44 with slight modifications. Briefly, brain tissues 
were homogenized in 10 volumes of Tris-buffered saline [TBS; 25 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM 
EGTA, protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitor cock-
tail (Roche Diagnostics)] and centrifuged in a TLA110 rotor (Beckman Coulter, Brea, CA, USA) at 27,433 × g 
for 20 min at 4 °C. The supernatant was collected as the TBS-soluble fraction. The pellet was resuspended in five 
volumes of high salt/sucrose buffer [10 mM Tris–HCl (pH 7.5), 0.8 M NaCl, 10% sucrose, and 1 mM EGTA]. 
The sample was then centrifuged at 27,433 × g for 20 min at 4 °C. The supernatant was transferred to a new tube, 
incubated in 1% sarkosyl at 37˚C for 1 h, and centrifuged at 149,361 × g for 1 h at 4 °C. The pellet was resus-
pended in 50 µL of TBS, sonicated, and collected as the sarkosyl-insoluble fraction.
Western blot analysis. Western blot analysis was conducted as described  previously19. The protein con-
centration of extracts was determined using a Protein Assay Bicinchoninate kit (Nacalai Tesque, Kyoto, Japan). 
TBS-soluble and sarkosyl-insoluble fractions were separated on precast polyacrylamide gels (Bolt Bis–Tris Plus 
Gels; Thermo Fisher Scientific, Waltham, MA, USA) and transferred to polyvinylidene difluoride membranes 
(iBlot 2 Transfer Stacks; Thermo Fisher Scientific). The membranes were blocked with 5% non-fat milk in TBS 
(25 mM Tris–HCl, pH 7.4, 0.9% NaCl) containing 0.1% Tween 20 for 1 h at room temperature and then incu-
bated overnight at 4 °C with primary antibodies including mouse monoclonal antibodies against tau (clone HT7; 
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1:2000; Thermo Fisher Scientific); tau phosphorylated at Ser202 and Thr205 (clone AT8; 1:1000; Thermo Fisher 
Scientific), at Thr212 and Ser214 (clone AT100; 1:1000; Thermo Fisher Scientific), at Thr231 (clone AT180; 
1:1000; Thermo Fisher Scientific), and at Thr181 (clone AT270; 1:1000; Thermo Fisher Scientific); this was fol-
lowed by addition of β-actin (1:5000; Santa Cruz Biotechnology, Dallas, TX, USA), along with rabbit polyclonal 
anti-tau antibody (1:2,000,000; DAKO, Glostrup, Denmark), which was produced by immunization with recom-
binant human tau protein expressed in Escherichia coli, corresponding to the C-terminal part (amino acids 
243–441) containing the four repeated sequences involved in microtubule binding. The membranes were further 
incubated with horseradish peroxidase-conjugated goat polyclonal antibody against mouse immunoglobulin 
(Ig)G (1:20,000; Jackson ImmunoResearch, West Grove, PA, USA) or rabbit IgG (1:20,000; Jackson ImmunoRe-
search) for 1 h. Immunoreactive proteins were visualized with a chemiluminescence substrate (SuperSignal West 
Pico PLUS Chemiluminescent Substrate; Thermo Fisher Scientific) using a lumino-image analyzer (LAS-4000 
mini; Fujifilm, Tokyo, Japan). The band density was analyzed using image processing software (ImageJ; National 
Institutes of Health, Bethesda, MD, USA). The amount of sample load in the sarkosyl-insoluble fraction was 
based on the initial wet weight of the extracted brain tissues.
Immunohistochemical analysis. The brain hemisphere was fixed in 4% paraformaldehyde for 24 h at 
4 °C, immersed in 0.1 M phosphate buffer (pH 7.4) containing 15% sucrose and 0.1% sodium azide for at least 
2 days for cryoprotection, and subsequently cut into 20-µm coronal sections with the use of a cryostat. Immu-
nohistochemical analysis was performed as described in previous  studies19,45. Briefly, free-floating sections were 
incubated with biotinylated antibodies against phosphorylated tau (clone AT8; 1:1000; Thermo Fisher Scien-
tific) and tau (clone HT7; 1:2000; Thermo Fisher Scientific) in PBS-T containing 0.2% bovine serum albumin 
overnight at 4  °C. The antibodies were detected using a Vectastain ABC Elite kit (1:1000; Vector Laborato-
ries, Burlingame, CA, USA) with 3,3′-diaminobenzidine (Dojindo Laboratories, Kumamoto, Japan) with nickel 
ammonium sulfate. The sections were scanned with a camera and the immunoreactive areas were quantified 
using ImageJ software.
Simplified Gallyas silver staining. Simplified Gallyas staining was performed as described in a previous 
 study46 with some  modifications19,45.
RNA isolation and quantitative polymerase chain reaction (qPCR). Total RNA was extracted from 
the cerebral cortex using an RNeasy Plus Universal Mini Kit (Qiagen, Hilden, Germany) in accordance with the 
manufacturer’s instructions. RNA samples were reverse transcribed into cDNA using SuperScript IV VILO Mas-
ter Mix (Thermo Fisher Scientific) in accordance with the manufacturer’s instructions. qPCR was conducted in 
duplicate 10-µL reactions containing 5 μl of THUNDERBIRD SYBR qPCR Mix (Toyobo, Osaka, Japan), 0.3 µM 
of each primer, and 0.5 ng of cDNA on a LightCycler 480 instrument (Roche Diagnostics) using the following 
cycling parameters: denaturation at 95 °C for 1 min, followed by 45 cycles of annealing at 95 °C for 15 s and 
extension at 60 °C for 30 s. Melting curve analysis confirmed that single amplicons were present and relative gene 
expression levels were determined using the ΔΔCT method with glyceraldehyde-3-phosphate dehydrogenase as 
the reference gene. Primer sequences are listed in Supplementary Table S5.
Plasmid construction and stable cell line development. Full-length human tau (0N4R) was cloned 
into the pcDNA3.1 vector acquired from human neuroblastoma cell line SH-SY5Y cDNA. A site-directed muta-
tion at P301L was introduced in the construct using the QuikChange Lightning Multi Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA, USA). The sequence of human tau with the P301L mutation was 
then subcloned into the pIRESpuro3 vector (Clontech Laboratories, Mountain View, CA, USA).
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (Nacalai Tesque) supplemented with 
10% (v/v) fetal bovine serum (Hyclone, Logan UT, USA), and kept at 37 °C under a humidified atmosphere of 
5%  CO2/95% air. Cells were seeded at 1 ×  105 cells/well in a 24-well plate. At 24 h after plating, the cells were 
transfected with the pIRESpuro3 vector containing human tau with the P301L mutation using Lipofectamine 
3000 reagent (Thermo Fisher Scientific). After a 24-h incubation period, the cells were transferred to a 6-cm 
culture dish, and stable cell lines were selected with 1 µg/mL puromycin (Nacalai Tesque) for 12 days. Single 
cells from resistant colonies were transferred into the wells of 96-well plates.
MID1 silencing with siRNA. HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(Nacalai Tesque) supplemented with 10% (v/v) fetal bovine serum (Hyclone, Logan UT, USA), and kept at 37 °C 
under a humidified atmosphere of 5%  CO2/95% air. Cells were seeded at 1 ×  105 cells/well in a 24-well plate. At 
24 h after plating, the cells were transfected with the pIRESpuro3 vector containing human tau with the P301L 
mutation using Lipofectamine 3000 reagent (Thermo Fisher Scientific). After a 24-h incubation period, the cells 
were transferred to a 6-cm culture dish, and stable cell lines were selected with 1 µg/mL puromycin (Nacalai 
Tesque) for 12 days. Single cells from resistant colonies were transferred into the wells of 96-well plates.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 7 software (GraphPad Soft-
ware, La Jolla, CA, USA). Data are presented as the mean ± standard error of the mean (SEM). Two-way ANOVA 
with genetic background and sex as factors was conducted. If the results of the two-way ANOVA revealed a main 
effect of the genetic background or sex, statistical significance was subsequently determined with the Mann–
Whitney U test for the corresponding single comparison. The Student’s t-test was used to identify significant 
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differences in the results of the cell culture experiments. A probability (p) value of < 0.05 was considered statisti-
cally significant.
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